Physiology and pharmacology of therapeutic botulinum neurotoxins.
Aoki
K Roger
KR
Neurotoxin Research Program, Biological Sciences, Allergan Inc., Irvine, Calif., USA. aoki_roger@allergan.com
D000344:Afferent Pathways / Q000187:drug effects; D000917:Antibody Formation; D000941:Antigens; D001905:Botulinum Toxins / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D002490:Central Nervous System / Q000187:drug effects; D006801:Humans; D009046:Motor Neurons / Q000187:drug effects / Q000502:physiology; D009465:Neuromuscular Agents / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D012449:Safety; D013563:Sympathectomy, Chemical
D000941:Antigens; D009465:Neuromuscular Agents; C096323:rimabotulinumtoxinB; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A; C096321:botulinum toxin type F